CN108948144A - 肽组合物的修饰以提高稳定性和递送效率 - Google Patents

肽组合物的修饰以提高稳定性和递送效率 Download PDF

Info

Publication number
CN108948144A
CN108948144A CN201810851248.7A CN201810851248A CN108948144A CN 108948144 A CN108948144 A CN 108948144A CN 201810851248 A CN201810851248 A CN 201810851248A CN 108948144 A CN108948144 A CN 108948144A
Authority
CN
China
Prior art keywords
peptide
cargo
carrier
therapeutic
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810851248.7A
Other languages
English (en)
Chinese (zh)
Inventor
德里克·麦克莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kai Pharmaceuticals Inc
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of CN108948144A publication Critical patent/CN108948144A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201810851248.7A 2007-01-19 2008-01-22 肽组合物的修饰以提高稳定性和递送效率 Pending CN108948144A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88141907P 2007-01-19 2007-01-19
US60/881,419 2007-01-19
US94528507P 2007-06-20 2007-06-20
US60/945,285 2007-06-20
CN2008800085591A CN101675067B (zh) 2007-01-19 2008-01-22 肽组合物的修饰以提高稳定性和递送效率

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2008800085591A Division CN101675067B (zh) 2007-01-19 2008-01-22 肽组合物的修饰以提高稳定性和递送效率

Publications (1)

Publication Number Publication Date
CN108948144A true CN108948144A (zh) 2018-12-07

Family

ID=39636771

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810851248.7A Pending CN108948144A (zh) 2007-01-19 2008-01-22 肽组合物的修饰以提高稳定性和递送效率
CN2008800085591A Active CN101675067B (zh) 2007-01-19 2008-01-22 肽组合物的修饰以提高稳定性和递送效率
CN201310359061.2A Pending CN103524623A (zh) 2007-01-19 2008-01-22 肽组合物的修饰以提高稳定性和递送效率

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2008800085591A Active CN101675067B (zh) 2007-01-19 2008-01-22 肽组合物的修饰以提高稳定性和递送效率
CN201310359061.2A Pending CN103524623A (zh) 2007-01-19 2008-01-22 肽组合物的修饰以提高稳定性和递送效率

Country Status (8)

Country Link
US (7) US8067532B2 (https=)
EP (2) EP3248985B1 (https=)
JP (7) JP2010516707A (https=)
KR (4) KR20090115852A (https=)
CN (3) CN108948144A (https=)
AU (1) AU2008206077A1 (https=)
CA (2) CA2989778C (https=)
WO (1) WO2008089491A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
JP5645408B2 (ja) 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
KR20090115852A (ko) * 2007-01-19 2009-11-09 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
WO2010111533A2 (en) * 2009-03-25 2010-09-30 Kai Pharmaceuticals, Inc. Transdermal delivery of pkc modulatory peptides through microporated skin
ES2729051T3 (es) 2009-07-29 2019-10-30 Kai Pharmaceuticals Inc Agentes terapéuticos para reducir los niveles de hormona paratiroidea
CN103857405B (zh) 2011-06-08 2015-12-02 凯伊药品公司 用于调节血清磷的治疗剂
EP2820150A1 (en) * 2012-03-01 2015-01-07 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
SMT201700401T1 (it) * 2013-06-28 2017-09-07 Amgen Inc Formulazione liquida stabile di amg 416 (velcalcetide)
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2986774A1 (en) 2015-05-29 2016-12-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
MX2018006610A (es) * 2015-12-02 2019-05-27 Inst Nat De La Rech Agronomique Inra Nuevos peptidos que tienen actividad antimicrobiana y nueva enzima capaces de convertir un residuo de configuracion l en un aminoacido de configuracion d en un peptido.
EP3411387A4 (en) 2016-02-03 2019-12-04 Kennesaw State University Research And Services Foundation Inc. SIGNAL MOLECULES AS A CELL PENETRANT
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
KR101772449B1 (ko) * 2016-12-27 2017-08-30 주식회사 하이센스바이오 신규한 펩타이드
WO2018134265A1 (en) 2017-01-17 2018-07-26 Forrest Michael David Therapeutic inhibitors of the reverse mode of atp synthase
WO2019012149A1 (en) 2017-07-13 2019-01-17 Forrest Michael David THERAPEUTIC MODULATORS OF THE INVERSE MODE OF ATP SYNTHASE
CA3079844A1 (en) 2017-11-10 2019-05-16 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors
US20210330738A1 (en) * 2018-03-29 2021-10-28 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
CN112533629A (zh) 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
GB201903873D0 (en) * 2019-03-21 2019-05-08 Univ Nottingham Enhanced transfection
CN114096554A (zh) 2019-07-02 2022-02-25 Ａｇｃ株式会社 肽及其制造方法
CN115175920B (zh) 2019-11-13 2025-10-31 阿穆尼克斯制药公司 加条形码的xten多肽及其组合物以及其制备和使用方法
WO2021195254A1 (en) * 2020-03-24 2021-09-30 Young Therapeutics, Llc Protein kinase c modulators
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
CN117999272A (zh) 2021-09-22 2024-05-07 Ａｇｃ株式会社 肽
KR102380732B1 (ko) 2021-09-23 2022-04-04 엘이솔루션 주식회사 축산분뇨처리시스템
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060153867A1 (en) * 2004-09-30 2006-07-13 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
CN103524623A (zh) * 2007-01-19 2014-01-22 凯制药公司 肽组合物的修饰以提高稳定性和递送效率

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615977A (en) * 1898-12-13 Car-fender
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5783405A (en) 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
AU741546B2 (en) * 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US20030108539A1 (en) 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
KR20020081330A (ko) * 2000-02-16 2002-10-26 노오쓰웨스턴 유니버시티 폴리펩토이드 폐 계면활성제
IL137290A0 (en) 2000-07-13 2001-07-24 Asher Eldad Ben An electronic circuit for reducing the danger of exposure to radiation from a transmitter
JP3710368B2 (ja) 2000-09-25 2005-10-26 シャープ株式会社 積層フィルムの製造方法
EP1324778A2 (en) * 2000-10-02 2003-07-09 Arizeke Pharmaceuticals, Inc. Compositions and methods for the transport of biologically active agents across cellular barriers
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
WO2002062396A2 (en) * 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20090075377A1 (en) * 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
WO2003084985A1 (fr) * 2002-04-11 2003-10-16 Mochida Pharmaceutical Co., Ltd. Peptide chimiquement modifie a l'aide de polyethyleneglycol
AU2003234185C1 (en) * 2002-04-22 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004047735A2 (en) * 2002-11-22 2004-06-10 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
AU2004215133B2 (en) 2003-02-27 2010-10-14 Yeda Research And Development Co. Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
WO2004084805A2 (en) * 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
CA2523672C (en) * 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
JP2007513974A (ja) * 2003-12-11 2007-05-31 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー プロテインキナーゼｃのアイソザイム特異的アンタゴニスト
AU2005271477A1 (en) 2004-08-02 2006-02-16 The Board Of Trustees Of The Leland Stanford Junior University Peptide sequence for modulation of delta protein kinase C
JP4596391B2 (ja) 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
CA2601823C (en) * 2005-04-15 2016-01-12 University Of Arizona Therapeutic peptides for the treatment of metastatic cancer
EP1934338A2 (en) * 2005-09-19 2008-06-25 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
US7579318B2 (en) * 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
US7741290B2 (en) * 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
AU2007305268A1 (en) * 2006-10-02 2008-04-10 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the C2 domain of epsilon PKC, and use thereof
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
CA2676340A1 (en) * 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060153867A1 (en) * 2004-09-30 2006-07-13 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
CN103524623A (zh) * 2007-01-19 2014-01-22 凯制药公司 肽组合物的修饰以提高稳定性和递送效率

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUO-PING HUANG，ET AL: "Modification of Protein by Disulfide S-Monoxide and Disulfide S-Dioxide Distinctive Effects on PKC", 《BIOCHEMISTRY》 *
郝一文: "蛋白激酶C调节血管内皮细胞CD44分子表达的机制", 《中国免疫学杂志》 *

Also Published As

Publication number Publication date
KR20170104634A (ko) 2017-09-15
US20160208237A1 (en) 2016-07-21
KR102274003B1 (ko) 2021-07-08
JP5937643B2 (ja) 2016-06-22
US9255124B2 (en) 2016-02-09
EP2109619B1 (en) 2017-05-03
US20200370032A1 (en) 2020-11-26
US20220282239A1 (en) 2022-09-08
CA2989778A1 (en) 2008-07-24
US20250034545A1 (en) 2025-01-30
JP2016147905A (ja) 2016-08-18
US20090042769A1 (en) 2009-02-12
JP2018111717A (ja) 2018-07-19
US8067532B2 (en) 2011-11-29
JP2023078424A (ja) 2023-06-06
US10077438B2 (en) 2018-09-18
CN103524623A (zh) 2014-01-22
KR20190140111A (ko) 2019-12-18
CA2675665C (en) 2018-02-13
JP2014224126A (ja) 2014-12-04
EP2109619A2 (en) 2009-10-21
US20180371448A1 (en) 2018-12-27
JP2021098725A (ja) 2021-07-01
AU2008206077A1 (en) 2008-07-24
JP2010516707A (ja) 2010-05-20
WO2008089491A3 (en) 2008-11-27
EP3248985A1 (en) 2017-11-29
US20120178138A1 (en) 2012-07-12
CA2989778C (en) 2020-06-30
CN101675067B (zh) 2013-09-11
EP2109619A4 (en) 2013-04-24
KR20090115852A (ko) 2009-11-09
EP3248985B1 (en) 2019-10-23
JP2025185093A (ja) 2025-12-18
WO2008089491A2 (en) 2008-07-24
KR101775929B1 (ko) 2017-09-07
CA2675665A1 (en) 2008-07-24
CN101675067A (zh) 2010-03-17
KR20160005377A (ko) 2016-01-14

Similar Documents

Publication Publication Date Title
CN108948144A (zh) 肽组合物的修饰以提高稳定性和递送效率
US10385108B2 (en) Peptide analogs of alpha-melanocyte stimulating hormone

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination